Ryan Scott

An expert from the University of Colorado (UC Health) comments on ongoing clinical trials which promise to shake up the treatment paradigm of endometrial cancer.

Oral decitabine, an oral fixed-dose of combination decitabine and CDA inhibitor cedazuridine, is an FDA-approved therapy for patients with lower-risk myelodysplastic syndromes.

An expert from Mount Sinai Hospital comments on potential new ruxolitinib combinations to treat patients with myelofibrosis and MPNs.

An expert from Dana-Farber Cancer Institute comments on ongoing research in translocation RCC and next steps for research in this treatment space.

Multidisciplinary approaches are still needed to proactively address the high relapse rates in patients with ovarian cancer treated with platinum-based chemotherapies, says Sanaz Memarzadeh, MD, PhD.

Allogeneic hematopoietic stem cell transplant (HSCT) is still the sole curative therapeutic modality for patients with myelofibrosis.

The efficacy and health-related quality of life benefits associated with the combination of lenvatinib and pembrolizumab make it a favorable treatment for advanced renal cell carcinoma, says an expert from Memorial Sloan Kettering Cancer Center.